While immunotherapy including programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) inhibitor are emerging therapies for metastasis and triple-negative breast cancer [34,35], CRP might also predict response to checkpoint inhibitor treatment for these patients [36]. The gene discussed is CTLA4; the disease is triple-negative breast carcinoma.